Balyasny Asset Management
RGNX icon

Balyasny Asset Management’s Regenxbio RGNX Stock Holding History

Balyasny Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-144,000
Closed -$2.37M – 2832
2023
Q3 		$2.37M Buy
144,000
+91,000
+172% +$1.65M ﹤0.01% 1333
2023
Q2 		$1.06M Buy
+53,000
New +$1.02M ﹤0.01% 1598
2019
Q1 		– Sell
-115,800
Closed -$4.86M – 1609
2018
Q4 		$4.86M Buy
+115,800
New +$6.79M 0.04% 511

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's RGNX Position: Q1 2026 in Review

Balyasny Asset Management increased its Regenxbio (RGNX) stake by 12% in Q1 2026, buying an estimated $12.9K and bringing the position to 11,656 shares worth $97.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2758.

Balyasny Asset Management first reported a position in RGNX in Q1 2018 and has held it in 18 quarters since. The position peaked at $13M in Q3 2023. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • Balyasny Asset Management held 11,656 shares of Regenxbio worth $97.7K as of Q1 2026.
  • Balyasny Asset Management bought 1,231 Regenxbio shares in Q1 2026, an estimated $12.9K.
  • Regenxbio made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2758 holding.
  • Balyasny Asset Management first reported a position in Regenxbio in Q1 2018 and has held it in 18 quarters since.
  • Balyasny Asset Management's Regenxbio position peaked at $13M in Q3 2023.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.